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Abstract Neurogenesis is essential for a good post-stroke
outcome. Exogenous stem cells are currently being tested to
promote neurogenesis after stroke. Elsewhere, we demonstrat-
ed that treatment with the PPARγ agonist pioglitazone (PGZ)
before cerebral ischemia induction reduced brain damage and
activated survival-related genes in ovariectomized (OVX)
rats. Here, we tested our hypothesis that post-ischemia treat-
ment with PGZ inhibits brain damage and contributes to
neurogenesis via activated stem cells. Bone marrow (BM)
cells of 7-week-old Wistar female rats were replaced with
BM cells from green fluorescent protein-transgenic (GFP+
BM) rats. Three weeks later, they were ovariectomized
(OVX/GFP+BM rats). We subjected 7-week-old Wistar male
and 13-week-old OVX/GFP+BM rats to 90-min cerebral ische-
mia. Male and OVX/GFP+BM rats were divided into two
groups, one was treated with PGZ (2.5 mg/kg/day) and the
other served as the vehicle control (VC). In both male and
OVX/GFP+BM rats, post-ischemia treatment with PGZ re-
duced neurological deficits and the infarct volume. In male
rats, PGZ decreased the mRNA level of IL-6 and M1-like
macrophages after 24 h. In OVX/GFP+BM rats, PGZ augment-
ed the proliferation of resident stem cells in the subventricular
zone (SVZ) and the recruitment of GFP+BM stem cells on days
7–14. Both types of proliferated stem cells migrated from the
SVZ into the peri-infarct area. There, they differentiated into
mature neurons, glia, and blood vessels in association with
activated Akt, MAP2, and VEGF. Post-ischemia treatment
with PGZ may offer a new avenue for stroke treatment
through contribution to neuroprotection and neurogenesis.
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Introduction
Brain ischemia is a leading cause of morbidity and mortality
[1]. Although thrombolysis for stroke is an accepted treat-
ment, fewer than 5% of stroke patients are treated with tissue
plasminogen activator. New therapeutic strategies are needed
for stroke patients.
While cerebral ischemia induces pro-inflammatory cy-
tokines, resulting in the expansion of brain damage, it stim-
ulates inherent neurogenesis in the subventricular zone
(SVZ) and promotes the migration of newly formed neu-
ronal progenitor cells toward the ischemic area [2]. This
process may help to repair the brain and reconstruct neural
networks. In rodents [3], monkeys [4], and humans [5], the
SVZ, located in the lateral wall lining the lateral ventricle,
harbors the largest population of neural stem cells capable
of generating new neurons, astrocytes, and oligodendro-
cytes. While enhanced neurogenesis and angiogenesis in
the SVZ and subgranular zone have been documented in
adult rodent brains after focal ischemia [6], as most of the
newly formed cells promptly undergo apoptosis, their ef-
fect on functional recovery is limited [2].
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The administration of pioglitazone (PGZ), a peroxi-
some proliferator-activated receptor gamma (PPARγ) ag-
onist, before cerebral ischemia induction protected ro-
dents against ischemic brain damage [7, 8]. Its benefi-
cial effects were associated with a decrease in the ex-
pression of interleukin-6 (IL-6) and caspase-3 and the
improvement of neurological function in male rats [7].
However, there are few studies regarding the effects of
post-ischemic treatment with PGZ.
As estrogen deficiency and menopause are thought to
be major risk factors for cerebral ischemia, in an earlier
study [8], we compared the effects of pre-treatment with
PGZ on cerebral ischemia in oophorectomized (OVX) and
non-OVX rats. We demonstrated that PGZ prevented is-
chemic brain damage in OVX rats when it was adminis-
tered before stroke and that this was associated with the
upregulation of anti-apoptotic and survival genes via the
trans-activation of STAT3 and PPARγ in the peri-infarct
region. This suggests its contribution to neurogenesis.
However, it remained to be determined whether post-
ischemic treatment with PGZ contributes to neurogenesis
and neurological improvement after an ischemic insult.
The local release of PGZ promoted wound healing [9]; the
regulation of monocytes/macrophages by PGZ inhibited
plaque destabilization and rupture in ApoE−/− mice [10], sug-
gesting that post-stroke treatment with PGZ may be useful.
Based on findings in other [7, 9, 10] and our studies [8], we
hypothesized that the activation of PPARγ elicited by the
administration of PGZ after stroke may be beneficial due to
not only its anti-inflammatory effects but also its promotion
of neurogenesis. As neurogenesis is regulated by the stem cell
niche [11], we focused on this issue. To examine whether
PGZ is associated with neuro- and angiogenesis, we prepared
female rats whose bone marrow (BM) cells were replaced
with BM cells from green fluorescent protein-transgenic
(GFP+BM) rats before oophorectomy (OVX/GFP+BM rats).
We first examined the neuroprotective effects elicited by
post-ischemia treatment with PGZ in male and OVX/GFP+
BM rats and then investigated its effects on neurogenesis in
OVX/GFP+BM rats.
Here, we show that even post-ischemia, early-phase treat-
ment with PGZ inhibits the infarct size and alleviates neuro-
logical deficits in male and in OVX/GFP+BM rats. We demon-
strate that the decrease in the pro-inflammatory cytokine IL-6
and in M1-like macrophages associated with an increase in
PPARγ after ischemia in male rats. We also document that in
OVX/GFP+BM rats, PGZ activated innate stem cells in the
SVZ and recruitment of GFP+BM stem cells with an increase
in PPARγ and then increased the expression of Akt, MAP2,
and VEGF in the cortical peri-infarct area, leading to
neurogenesis.
Materials and Methods
Our study was approved by the Ethics Committee of the
Institute of Biomedical Sciences, Tokushima University
Graduate School, and conducted in accordance with current
RIGOR guidelines [12, 13] and the National Institutes of
Health (NIH) Guide for the Care and Use of Laboratory
Animals. We purchased male and female Wistar rats from
Charles River Laboratories Japan Inc. (Yokohama, Japan).
They were housed in conventional rat cages in a
temperature- and humidity-controlled room (about 23 °C
and 50%, respectively) under a 12-h inverted light/dark cycle
and were fed standard chow. Anesthesia was with 2%
isofluorane in 30% oxygen and 70% nitrous oxide. The ex-
periments were reported according to the BAnimal Research:
Reporting of In Vivo Experiments (ARRIVE)^ guidelines to
improve the design, analysis, and reporting of research using
animals—maximizing information published and minimizing
unnecessary studies. All procedures were performed by inves-
tigators blinded to the treatment that rats had undergone ac-
cording to a protocol approved by the Animal Care
Committee of TokushimaUniversityMedical School. For ran-
domization, we used random-number tables; the treatment
groups were identified by ear punch and the cages were
labeled.
Whole-Body Irradiation and BM Transplantation
in Female Rats
The BM donors were 6-week-old GFP-transgenic rats pur-
chased from Japan SLC, Inc. (Hamamatsu, Japan). They were
killed under deep anesthesia by cervical dislocation. BM was
obtained by flushing the femora and tibiae with sterile
phosphate-buffered saline (PBS). BM cells were suspended in
PBS, washed several times, counted, and resuspended at 4 × 107
cells/ml. All procedures were as described elsewhere [14].
At the age of 7 weeks, the Wistar female rats underwent
whole-body irradiation with a single 10-Gy dose. Within 24 h,
thereafter, they were injected with 300 μl of the GFP-labeled
BM cell suspension via the tail vein.
Animals
Females received BM cells fromGFP rats who were subjected
to bilateral OVX at the age of 10 weeks (OVX/GFP+BM rats).
Based on our and other earlier studies [7, 8], 7-week-old male
and 13-week-old OVX/GFP+BM Wistar rats weighing 250–
270 g and 280–300 g, respectively, were subjected to 90-
min middle cerebral artery occlusion-reperfusion (MCAO-
R). One group of randomly selected rats was injected intra-
peritoneally (i.p.) with 2.5 mg/kg/day PGZ; the other was the
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vehicle control (VC). In male and OVX/GFP+BM rats, we
recorded the effects of PGZ delivered in the early phase after
MCAO-R (day 0) and once a day for 7 (males) and 14 con-
secutive days (OVX/GFP+BM rats).
Besides examining the response to early-phase post-ische-
mia treatment with PGZ in OVX/GFP+BM rats, we also
assessed its effect on post-MCAO-R regeneration on days
7–14. The OVX/GFP+BM rats were randomly sub-divided into
two groups: one group received 2.5 mg/kg PGZ i.p. once a
day for 14 consecutive days after MCAO-R, the other served
as the VC. PGZ, a gift from Takeda Pharmaceutical Co., was
dissolved in dimethylsulfoxide (DMSO) and diluted (× 3)
with saline just before i.p. injection (0.4 ml/kg body weight).
VC rats were injected DMSO dilution at the same concentra-
tion and volume as PGZ.
Focal Cerebral Ischemia
During all surgical procedures, the rats were under anesthesia
with 2% isofluorane in 30% oxygen and 70% nitrous oxide;
their rectal temperature was monitored with a thermometer
(KN-91, Natsume) and maintained at 37 ± 0.5 °C with a
warming plate.
For 90-minMCAO, we inserted an intraluminal filament as
described elsewhere [15, 16]. To block major collateral flow,
the pterygopalatine artery was ligated at its origin. The internal
and common carotid artery were transiently occluded with
loosely tied 3–0 silk sutures; a silicon-coated 4–0 nylon thread
was introduced into the external carotid artery and advanced
into the internal carotid artery to occlude the proximal orifice
of the MCA. To confirm MCAO, we used a laser-Doppler
flow probe (Unique Medical, Osaka, Japan) to measure the
blood flow at the temporal bone surface at a site 1 mm poste-
rior to the bregma and 3 mm inferior to the temporal line.
MCAO reduced the blood flow to 20–30% of the baseline.
Rats with successful MCAO-R consistently exhibited cir-
cling behavior, decreased resistance to lateral push, forelimb
flexion, and shoulder adduction. We excluded around 10% of
the rats because MCAO-R was incomplete. Blood glucose
levels were determined in whole venous blood with an auto-
matic glucose meter (Accu-check Aviva blood glucose meter,
Roche Diagnostics, Tokyo, Japan). The blood pressure was
measured by telemetry (Data Science Inc., MN55126, USA)
before, during, and after MCAO-R and recorded using the
Dataquest Advanced Research Technologies Acquisition pro-
gram (Unique Medical).
Measurement of the Infarct Volume
The brains were extracted and equal 2-mm-spaced slices and
six coronal blocks were prepared immediately using a brain
matrix (Bioresearch Center, Nagoya, Japan). The samples did
not contain olfactory tissue or tissue from the cerebellum. All
but the 3rd coronal sections were immersed in a 2,3,5-triphe-
nyltetrazolium chloride (TTC) solution in PBS to detect the
infarct area. We identified the area surrounding the infarct area
in the frontal cortex as the peri-infarct area. The tissue samples
were stored at − 80 °C until Western blot analysis and deter-
mination of the mRNA level. The extent of ischemic infarc-
tion was traced manually, and the integrated volume was cal-
culated using NIH 1.36b Image J software. Artifacts from
brain edema were eliminated by applying the indirect mea-
surement method based on the contralateral brain volume.
Neurological Assessment
Neurological deficits were assessed by an examiner blinded to
the treatment the rats had undergone. We modified the neuro-
logical scoring system of Huang et al. [17] and Chen et al. [18]
and recorded our findings as 0 = normal; 1 = forelimb or
hindlimb flexion, head turned > 10 to the vertical axis within
30 s after raising the rat by the tail, inability to walk straight on
the floor, and grasping the side of the beam during the beam
balance test; 2 = circling toward the paretic side, one limb
falling off the beam; 3 = falling to the paretic side, hugging
the beam, and two limbs falling off the beam; 4 = attempting
to balance on the beam but falling off (> 40 s); 5 = attempting
to keep balance on the beam but falling off (> 20 s); and 6 =
falling off the beam without attempting to balance or hang on
to the beam (< 20 s). The rats were evaluated immediately
after successful MCAO, 24 h after MCAO-R, and again on
days 1, 3, and 7 (males) and on days 1, 3, 7, and 14 (OVX/
GFP+BM rats) after treatment with PGZ or VC. The total max-
imum score was 12.
Quantitative Real-Time PCR
Total RNA obtained from the peri-infarct area was isolated
with the BioRobot EZ1 and EZ1 universal tissue kit
(Qiagen, Tokyo, Japan). RNAwas converted to cDNA using
the transcript first-strand cDNA synthesis kit (Qiagen).
Quantitative real-time PCR assay of each sample was on
Light Cycler FastStart DNA Master SYBR Green I and
Roche LightCycler 2.0 (Roche Diagnostics, Tokyo, Japan)
instruments. Primers for GAPDH were from Roche and used
according to the manufacturer’s directions. The other primers
were: for rat IL-6, forward (F), 5′-TCT CAG GGA GAT CTT
GGA AAT G-3′, reverse (R), 5′-TAG AAA CGG AAC TCC
AGA AGA C-3′; for rat TNF-α, (F), 5′-CCC AAC AAG
GAG GAG AAG T-3′, (R), 5′-CGC TTG GTG GTT TGC
TAC-3′; for rat IL-1β, (F), 5′-TGC AGG CTT CGA GAT
GAA C-3′ (R), 5′-AGC TCA TGG AGA ATA CCA CTT
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G-3′; for rat VEGF, (F), 5′-CACATAGGAGAGATGAGCTT-
3′, (R), 5′-CTGGCTTTG TTCTATCTTTC-3′. The amplified
product was separated on 1.5% agarose gels containing EtBr
solution (Wako, Osaka, Japan) and visualized on an ultraviolet
transilluminator. The results were normalized to the expres-
sion of GAPDH mRNA.
Immunohistochemistry
The rats were transcardially perfused with 4% paraformalde-
hyde in PBS on ice. Their brains were fixed and 6-μm-thick
frozen sections were mounted on Matsunami adhesive silane
(MAS)-coated glass slides (Matsunami Glass, Tokyo, Japan),
blocked with serum-free protein (DakoCytomation), and then
the slides were incubated with primary antibodies diluted with
Canget signal immunostain (Toyobo, Osaka, Japan). The an-
tibodies were rabbit polyclonal antibody against PPARγ
(Abcam, Tokyo, Japan), GFAP, Nestin, MAP2, (Santa Cruz
Biotechnology), and antibodies against GFP (Cell Signaling
Technology). We used mouse monoclonal antibody against
neuronal nucleus (NeuN) (Millipore, Tokyo, Japan),
Musashi-1 (AbD Serotec), CD16, CD68 (Santa Cruz
Biotechnology), CD31 (MAB1393, CHEMICON, MA), cas-
pase-3, GFP, and Nestin (Cell Signaling Technology). The
tissue samples were mounted with Vectashield (Vector
Laboratories Inc., Burlingame, CA). Visualization was with
Alexa Fluor 594 donkey anti-rabbit IgG or 488 goat anti-
mouse IgG (Molecular Probes, Eugene, OR); the slides were
examined under a fluorescence microscope (KEYENCE, BZ-
X710, Osaka, Japan). To examine the specificity of immuno-
reactivity, the primary antibody was omitted to provide a non-
specific control. A parallel set of tissue sections was subjected
to hematoxylin and eosin staining to identify the infarct core
and the peri-infarct region. We counted all cells positive for
Musashi-1 and GFP in the peri-infarct area. Images were cap-
tured at ×10 magnification under the microscope. In each an-
imal, we randomly selected two areas containing positive cells
in 150 × 150-μm fields around the peri-infarct area. Tissue
samples from four rats in each group were analyzed by den-
sitometry of the positive cells using BZH-3A (KEYENCE)
analysis software.
Bromodeoxyuridine (BrdU) Labeling in OVX/GFP+BM
Rats
We recorded the time course of proliferating cells in the brain
after cerebral ischemia by pulse-labeling. BrdU, a thymidine
analogue that is incorporated into the DNA of dividing cells
during the S-phase, was used for mitotic labeling (Sigma
Chemical) [19]. We applied a cumulative labeling method to
examine the population of proliferating cells in OVX rats ex-
posed for 14 days to cerebral ischemia and injected BrdU
(50 mg/kg, i.p.) every 4 h for 12 h before killing the rats on
the 1st, 3rd, 7th, or 14th day after the induction of cerebral
ischemia (n = 6 each). BrdU-positive cells were detected
immunohistochemically using sheep polyclonal antibody
BrdU (LifeSpan BioSciences Inc.) as the primary and donkey
anti-sheep IgG (Molecular Probes, Eugene, OR) as the sec-
ondary antibody.
Western Blot Analysis in OVX/GFP+BM Rats
Brain tissue in the peri-infarct area was homogenized and
sonicated in RIPA buffer (Thermo Scientific, Rockford, IL)
containing phosphatase and protease inhibitors (Roche,
Tokyo, Japan) and centrifuged. Total protein in the superna-
tant was measured with the BCA protein assay kit (Pierce,
Rockford, IL). Protein was separated by 7.5 or 12% SDS-
PAGE and transferred to a polyvinylidenedifluoride mem-
brane. After blocking with 5% skim milk or BSA in Tris-
buffered saline solution-Tween 20 (T-TBS), the membrane
was incubated with the primary antibodies in Canget signal
immunostain or T-TBS. The same primary antibodies as used
for the immunohistochemical studies, rabbit polyclonal anti-
body against p-Akt (Cell Signaling Technology), MAP2, and
mouse monoclonal anti-β-actin (Sigma, Tokyo Japan) were
used. After incubation with horseradish peroxidase-
conjugated secondary antibodies (GE Healthcare,
Buckinghamshire, UK), signals were detected by chemilumi-
nescence using an ECL-plus kit (GEHealthcare). Images were
analyzed with Image Quant LAS 4000 mini (GE Healthcare)
and Image J software and quantified as the relative increase
over the controls after normalization with β-actin.
Statistical Analysis
Power estimates were calculated based on α = 0.05,
1-β = 0.8, and a surgery-related drop-out rate of around
10% to obtain group sizes appropriate for detecting an
effect size of 0.4 based on a preliminary experiment using
G*Power 3.1. The infarct volume and the neurological
score were analyzed with Student’s t test and Man-
Whitney U test, respectively; their correlation was
assessed by the Spearman’s rank-correlation coefficient.
The mRNA expression levels were determined with anal-
ysis of variance (ANOVA) followed by Scheffe’s test for
three-group comparisons. Statistical analyses were per-
formed using IBM SPSS Statistics 22. Data are shown as
the mean ± SD. Differences were considered statistically
significant at p < 0.05.
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Results
Male Rats: Treatment with PGZ in the Early
Post-ischemia Phase Reduced the Cerebral Infarct Size
and Ameliorated Neurological Deficits by Inhibiting
Pro-inflammatory Responses
We first assessed the effects of PGZ treatment in the early
phase after experimental cerebral ischemia. Compared to the
VC males, on days 1–7 after the ischemic insult, PGZ rats
manifested a lower neurological score and earlier recovery
of the body weight loss (Fig. 1a, b). The infarct volume was
smaller than in VC rats (Fig. 1c) and correlated with the neu-
rological score (Fig. 1d). Next, to address the mechanisms
underlying the effects of PGZ, we examined its anti-
inflammatory effects against brain ischemic injury. In VC rats,
the mRNA level of IL-6, IL-β, and TNFα was increased 3 h
after ischemia induction and augmented at 24 h (Fig. 2a–c). In
PGZ rats, the mRNA level of IL-6 (Fig. 2a) but not of IL-β
and TNFα was significantly decreased at 3 and 24 h (Fig. 2b,
c). Immunohistochemically, the expression of PPARγ was
higher in PGZ than VC rats; CD16- and CD68-positive cells
were fewer and the expression of caspase-3 was lower
(Fig. 2d). PPARγ was localized in CD31-positive cells.
CD16-positive cells were Iba-1 or CD68 positive. Treatment
with PGZ in the early phase post-ischemia appeared to exert
beneficial effects through anti-apoptosis and anti-
inflammatory response effects elicited by the expression of
PPARγ.
OVX/GFP+BM Rats: Increased PPARγ Expression
Elicited by PGZ Was Associated with Neuroprotection
and the Activation of Resident Stem Cells in the SVZ
and the Recruitment of BM Cells
Our earlier study in ovariectomized (OVX) rats treated with
PGZ before ischemia induction suggested neurogenesis in the
post-ischemic phase [8]. To examine the role in neuroprotec-
tion and neurogenesis of early-phase PGZ treatment after is-
chemia induction, we used OVX/GFP+BM rats whose BM
cells were replaced by BM cells from GFP rats. While 75%
of the VC-OVX/GFP+BM rats died within 14 days after
MCAO-R, all OVX/GFP+BM rats treated with PGZ (PGZ rats)
survived (n = 12 in each group). On days 1, 3, 7, and 14 after
MCAO-R, the cerebral infarct volume was significantly
smaller in PGZ than VC rats (p < 0.05, Fig. 3a) and their
neurological deficits were significantly less pronounced
(p < 0.05, Fig. 3b), indicating neuroprotection by early-
phase PGZ treatment. There was no significant difference in
the cerebral blood flow, blood glucose levels, and blood pres-
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Fig. 1 Effects of PGZ against
brain damage in male rats. Post-
ischemia treatment with PGZ or
vehicle was performed immedi-
ately after MCAO induction on
day 0 and once a day for 7 con-
secutive days. The neurological
scores (a), body weight (b), and
infarct volume (c) were recorded
in PGZ- and vehicle-treated male
rats. The infarct volume was re-
corded as a percentage of the
contralateral hemisphere using
Image J software (each group
n = 12). The correlation between
the infarct volume and neurologi-
cal deficits was assessed by
Spearman’s rank-correlation co-
efficient (d). Each bar represents
the mean ± SD. *p < 0.05 vs. VC
by ANOVA followed by
Scheffe’s test. MCAO-R middle
cerebral artery occlusion-reperfu-
sion, VC vehicle control, PGZ
2.5 mg/kg pioglitazone
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Compared to the contralateral non-ischemic side of VC
rats, on days 3 and 7 post-MCAO-R, the expression of
PPARγ and of Musashi-1- and GFP-positive cells was in-
creased in the SVZ on the infarct side of PGZ rats (Fig. 3c).
The expression of PPARγ in the SVZ seemed to be associated
with an increase in innate stem cells and the recruitment of
allogeneic BM-derived stem cells.
OVX/GFP+BM Rats: PPARγ Activation Promoted
the Proliferation of Stem Cells in the SVZ and their
Translocation to the Peri-infarct Region
As shown in Fig. 4a, on the 7th day after ischemia induction,
nestin-positive cells were detected in the SVZ and the cortical
peri-infarct area of PGZ rats; the cells seemed to migrate from
the SVZ to the peri-infarct region. The number of
translocated Musashi-1-positive- and of GFP-positive cells
was significantly higher in PGZ than VC rats (p < 0.05,
Fig. 4b) and associated with the increase in NeuN- and
GFAP-positive cells. These cell populations seemed to in-
clude both resident stem cells in SVZ and recruitment of
BM-derived stem cells replaced by allogeneic BM cells. We
immunohistochemically assessed the incorporation of the cell
proliferation marker BrdU in the stem cells. The presence of
many BrdU-labeled Musashi-1- and GFP-positive cells was
evidence for the proliferation of stem cells in the peri-infarct
region (Fig. 4c). PPARγ activation may promote not only the
proliferation of stem cells in the SVZ but also the migration





Fig. 2 The mRNA level of pro-inflammatory cytokines and representa-
tive immunohistochemistry findings in PGZ- and VC-treated male rats.
The mRNA level of the pro-inflammatory cytokines IL-6 (a), TNFα (b),
and IL-1β (c) was assessed by quantitative real-time PCR assay and
normalized by GAPDH. Data obtained 3 and 24 h after MCAO-R are
shown. Data are the mean ± SD from eight rats per group. *p < 0.05 vs.
VC by ANOVA followed by Scheffe’s test. The expression of PPARγ,
CD16, CD68, and caspase-3 was examined in the peri-infarct region of
PGZ-treated and VC rats 24 h after MCAO (d). PPARγ- and CD16-
positive cells were co-localized with VEGF-, Iba-1- or CD68-positive
cells
Transl. Stroke Res. (2018) 9:306–316 311
OVX/GFP+BM Rats: Proliferated Neuronal Stem Cells
Differentiated into Blood Vessels, Neurons, and Glia
in the Cortical Peri-infarct Region Via the Upregulation
by PGZ of the Survival Signal Pathway
Lastly, we examined the effects of PPARγ activation by PGZ
on neurogenesis. Some of the Musashi-1- and GFP-positive
cells were NeuN, GFAP, or CD-31 positive (Fig. 5a, b). BrdU-
labeled cells were also NeuN, GFAP, or CD-31 positive and
some of them were mature, and seen in neurons, glia, and
blood vessels. Extended axons were also observed
(Figs. 5a–c, 6), suggesting that PGZ promoted the differenti-
ation into mature neurons, glia, and blood vessels in the cor-
tical peri-infarct region.
Examination of the gene and protein expression of
survival- and proliferation-related molecules elicited by
treatment with PGZ showed that on days 7 and 14, the
mRNA level of VEGF was increased in the peri-infarct
region (p < 0.05, Fig. 5d). Consequently, the expression
of VEGF, MAP2, and p-Akt was significantly higher in
PGZ than VC rats (p < 0.05, Fig. 5e). These findings sug-
gest that the upregulation by PGZ of survival signaling
pathways was associated with the proliferation of neuronal
stem cells and their differentiation into mature neurons,
glia, and blood vessels.
Discussion
We first demonstrate that post-ischemia treatment with PGZ in
early phase prevented the expansion of brain injury and atten-
uated neurological deficits in male and OVX/GFP+BM rats.
We showed that the neuroprotective effects of PGZ in the
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Fig. 3 Effects of post-ischemia treatment with PGZ in OVX/GFP+BM
rats. PGZ or vehicle (VC) was administered immediately after MCAO
induction on day 0 and once a day for 14 consecutive days. The infarct
volume (a) was recorded in OVX/GFP+BM rats treated with PGZ or VC
(each group n = 12). The neurological score (b) was assessed as described
in Materials and Methods. Each bar represents the mean ± SD *p < 0.05
vs. VC by ANOVA followed by Scheffe’s test. Representative immuno-
histochemistry findings for PPARγ, Musashi-1, and GFP (d) in the SVZ
after MCAO-R
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inflammatory response involving a decrease in IL-6 and M1-
type macrophages in male rats. Furthermore, we found that in
OVX/GFP+BM rats PGZ promoted the proliferation of both
innate stem cells in the SVZ and BM-derived stem cells and
their translocation from the SVZ into the cortical peri-infarct
region on days 7–14 of post-ischemia. This was associated
with the high expression of VEGF, MAP2, and p-AKT and
an increase in PPARγ in the peri-infarct area and the differen-
tiation of stem cells into mature cells, resulting in the allevia-
tion of neurological dysfunction. Our findings suggest that
early-phase treatment with PGZ, even after experimentally
induced cerebral ischemia, contributed to a good stroke out-
come in rats via its anti-inflammatory effects and the elicita-
tion of neurogenesis (Fig. 6).
Lambertsen et al. [20] who studied experimental and hu-
man stroke, reported that within 1–6 h post-ischemia, the
protein level of IL-1β and TNFα but not of IL-6 was in-
creased in the brain and cerebrospinal fluid and persisted at
high levels until 24 h. In our animal study, the mRNA level of
IL-6, TNFα, and IL-1β was increased 24 h after ischemia
induction; this was associated with the presence of M1-like
macrophages and the expansion of cerebral infarction al-
though the mRNA level of IL-6 was low during the first 3 h.
PGZ suppressed the expression of IL-6 at 24 h without affect-
ing TNFα and IL-1β. During the early post-ischemic phase in
male rats, the different effects of PGZ against these molecules
may be associated with their different expression profile after
ischemia and the timing of PGZ treatment. Nakashiro [10]
reported that PGZ decreased the expression of circulating in-
flammatory monocytes. As PGZ inhibited the expression of
CD16+/CD68+M1-like macrophages in our rats, we think that
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Fig. 4 Stem cells migration from the SVZ into the cortical peri-infarct
region promoted by PGZ in OVX/GFP+BM rats. Representative nestin-
positive cells in the SVZ and the cortical peri-infarct region on day 7 after
ischemia induction in PGZ-treated OVX/GFP+BM rats (a). Cells positive
for Musashi-1, GFP, NeuN, and GFAP were detected in the infarct- and
the peri-infarct area (b). Musashi-1- and GFP-positive cells were counted
in 150 × 150-μm fields. The total cell number (n) in each area was 140–
160 cells for DAPI. Each bar represents the mean ± SD from two areas in
each of four rats. *p < 0.05 vs. VC byANOVA followed by Scheffe’s test.
Representative Musashi-1- and GFP-positive cells incorporated BrdU (c)
Transl. Stroke Res. (2018) 9:306–316 313
of M1-like monocyte-derived macrophages from the
perivascular area into the brain. According to Patzer et al.
[21], IL-6-expressing microglia/macrophages in the brain
were activated in the initial post-ischemic stage and immuno-
histochemical and Western blot analysis showed that PGZ
reduced the expression of IL-6. Thus, the down-regulation
of IL-6 in the early post-ischemic phase may be crucial for a
reduction in ischemic brain damage.
Although we do not know how PGZ increases the expres-
sion of PPARγ in areas adjacent to the SVZ, elsewhere [8], we
demonstrated that treatment with PGZ before ischemia induc-
tion upregulated STAT3 and increased the expression of anti-
apoptotic bcl-2 and VEGF. IL-6 is associated with the JAK/
STAT pathway and elicits a pro-inflammatory response in the
early phase; in the late phase, it is associatedwith neurotrophic
effects [22]. The regulation of IL-6 by PGZ may exert ambiv-
alent beneficial effects in the early and late phase after stroke.
Neuronal stem cells are primordial, multipotent, self-
renewing cells that give rise to differentiated progeny within
all neuronal and glial lineages. They continue to produce new
neurons throughout life in the SVZ and the dentate gyrus of
the hippocampus [19, 23]. However, most of the newly
formed cells promptly undergo apoptosis, possibly due to un-
favorable conditions after cerebral ischemia and the lack of
adequate trophic support [6]. In contrast, PGZ-induced stem
cells seem to be less affected by ischemic conditions. The
increased expression of MAP2 and p-Akt elicited by PGZ
and the upregulation of anti-apoptotic genes [8] might contrib-
ute to the activation of survival signaling pathways to nourish
the stem cells. Thus, the activation of PPARγ by PGZ after the
ischemic insult may not only accelerate the proliferation of
resident stem cells in the SVZ and the recruitment of BM-
derived stem cells but may also contribute to their differenti-
ation in the peri-infarct area.
Neurotrophic factors regulate the survival, proliferation,
and differentiation of cells in the central nervous system [6,
23]. VEGF, identified as an angiogenic and vascular perme-
ability factor, is recognized as a neurotrophic factor [24]
whose role depends on its temporal and spatial profiles.
During the acute phase of ischemic injury, the upregulation
of VEGF in cerebral vessels increases the permeability of the
blood-brain-barrier, thereby exacerbating ischemic cell dam-
age [25]. At a later stage after stroke, it triggers angiogenesis,






















































































Fig. 5 Stem cells differentiation into blood vessels, neurons, and glia via
the upregulation of the survival signal pathway induced by PGZ in OVX/
GFP+BM rats. In the peri-infarct region, double immunohistochemical
staining for Musashi-1 (a), GFP (b), and BrdU (c) shows co-
localization with NeuN, GFAP, and CD31, respectively. ThemRNA level
of VEGF (d) was analyzed by quantitative PCR. The protein expression
of VEGF, p-Akt, and MAP2 in the peri-infarct region (e) was detected on
Western blots and analyzed using LAS 4000 and Image J software. Data
are the mean ± SD from eight rats per group. *p < 0.05 vs. VC by
ANOVA followed by Scheffe’s test
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neurogenesis [26]. Despite the high expression of PPARγ
elicited by PGZ in both the early and late phase after the
ischemic insult imposed on our rats, the VEGF expression
pattern was different in these phases. The upregulation of
VEGF on days 7 and 14 may have contributed to angiogene-
sis. The phosphatidylinositol-3 kinase (PI3)/Akt signaling
pathway plays a central role in regulating the growth, prolif-
eration, and survival of cells under physiological and patho-
physiological conditions. Its activation protects vascular func-
tion [27], promotes cell survival, and suppresses apoptosis. As
did others [28, 29], we found that treatment with PGZ even
after an ischemic insult increased the expression of p-Akt and
MAP2 in the peri-infarct region. Therefore, elicitation of an-
giogenesis and neurogenesis may be attributable to the upreg-
ulation of survival signaling pathways by PGZ.
Although attempts to promote neurogenesis by injecting
exogenous stem cells have remained unsuccessful, the com-
bined delivery of PGZ and exogenous stem cells may help to
promote neurogenesis. We need further studies to determine
whether PGZ helps to promote the survival and proliferation
of exogenous stem cells. Kernan et al. [30] reported that 4.8-
year PGZ treatment of patients with insulin resistance, ische-
mic stroke, and transient ischemic attacks reduced the risk for
recurrent stroke or myocardial infarcts but increased the risk
for weight gain, edema, and bone fracture. Therefore, the con-
dition of patients treated with PGZ must be monitored care-
fully, and its administration should be short term.
In conclusion, we provide new evidence that PGZ treatment
in the early phase after an experimentally induced ischemic
insult ameliorated neurological dysfunction and suppressed
the infarct size in male and OVX/GFP+BM rats. We show that
its beneficial effects were associated with the induction of anti-
inflammatory responses in the early and with the elicitation of
angiogenesis and neurogenesis in the late post-ischemic phase.
Treatment with PGZ in the early post-ischemic phase may help
to limit ischemic brain damage and to alleviate neuronal defi-
cits.We are continuing to assess the potential role of PGZ in the
activation of post-stroke PPARγ because such findings may
lead to treatments that improve the outcomes in stroke patients.
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